DaVita, Inc. Hits New 52-Week High of $239.12, Showcasing Strong Growth

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 239.12 on July 13, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 66.39%, significantly outpacing the S&P 500's growth of 20.06% during the same period. The company's market capitalization stands at USD 11,513 million, reflecting its position within the small-cap category. DaVita's price-to-earnings (P/E) ratio is currently at 11.00, indicating its valuation relative to earnings. However, the company does not offer a dividend yield, and its debt-to-equity ratio is reported at -15.25, suggesting a unique financial structure. Additionally, DaVita's return on equity is notably low at -163.56%, and its price-to-book ratio is at -17.68, which may indicate challenges in asset valuation. Overall, DaVita's recent price movement and performance metrics highlight its current standing in the market, marking a noteworthy achievement in its financial journey.